PNC Financial Services Group
RPRX icon

PNC Financial Services Group’s Royalty Pharma RPRX Stock Holding History

PNC Financial Services Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$989K Buy
17,630
+1,699
+11% +$88.4K ﹤0.01% 1402
2026
Q1 		$764K Buy
15,931
+2,597
+19% +$114K ﹤0.01% 1431
2025
Q4 		$515K Sell
13,334
-29
-0.2% -$1.11K ﹤0.01% 1638
2025
Q3 		$471K Buy
13,363
+235
+2% +$8.51K ﹤0.01% 1680
2025
Q2 		$473K Buy
13,128
+463
+4% +$15.3K ﹤0.01% 1604
2025
Q1 		$394K Buy
12,665
+859
+7% +$27.2K ﹤0.01% 1694
2024
Q4 		$301K Buy
11,806
+4,129
+54% +$109K ﹤0.01% 1901
2024
Q3 		$217K Sell
7,677
-223
-3% -$6.18K ﹤0.01% 2124
2024
Q2 		$208K Sell
7,900
-4,425
-36% -$123K ﹤0.01% 2117
2024
Q1 		$374K Buy
12,325
+1,378
+13% +$40.6K ﹤0.01% 1723
2023
Q4 		$308K Buy
10,947
+5,438
+99% +$149K ﹤0.01% 1835
2023
Q3 		$150K Buy
5,509
+536
+11% +$15.9K ﹤0.01% 2324
2023
Q2 		$153K Buy
4,973
+337
+7% +$11.4K ﹤0.01% 2387
2023
Q1 		$167K Buy
4,636
+1,256
+37% +$46.6K ﹤0.01% 2254
2022
Q4 		$134K Sell
3,380
-564
-14% -$23.5K ﹤0.01% 2390
2022
Q3 		$159K Buy
3,944
+558
+16% +$23.8K ﹤0.01% 2238
2022
Q2 		$142K Sell
3,386
-37
-1% -$1.52K ﹤0.01% 2342
2022
Q1 		$133K Buy
3,423
+1,208
+55% +$47.4K ﹤0.01% 2528
2021
Q4 		$88K Buy
2,215
+1,627
+277% +$63.2K ﹤0.01% 2767
2021
Q3 		$20K Buy
588
+86
+17% +$3.34K ﹤0.01% 3504
2021
Q2 		$20K Buy
502
+226
+82% +$9.61K ﹤0.01% 3475
2021
Q1 		$12K Buy
276
+116
+73% +$5.5K ﹤0.01% 3596
2020
Q4 		$8K Buy
+160
New +$6.79K ﹤0.01% 3628

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PNC Financial Services Group's RPRX Position: Q2 2026 in Review

PNC Financial Services Group increased its Royalty Pharma (RPRX) stake by 11% in Q2 2026, buying an estimated $88.4K and bringing the position to 17,630 shares worth $989K. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

PNC Financial Services Group first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • PNC Financial Services Group held 17,630 shares of Royalty Pharma worth $989K as of Q2 2026.
  • PNC Financial Services Group bought 1,699 Royalty Pharma shares in Q2 2026, an estimated $88.4K.
  • Royalty Pharma made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #1402 holding.
  • PNC Financial Services Group first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.